Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Liu QW"" wg kryterium: Autor


Wyświetlanie 1-5 z 5
Tytuł :
Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
Autorzy :
Ou W; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Li N; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Experimental Research, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Wang SY; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Li J; Department of Ultrasound, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Liu QW; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Huang QA; Department of Thyroid and Breast Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Wang BX; Breast Tumor Center, Sun Yat-sen Memorial Hospital; Sun Yat-sen University, Guangzhou, China.
Pokaż więcej
Źródło :
Cancer [Cancer] 2016 Mar 01; Vol. 122 (5), pp. 740-7. Date of Electronic Publication: 2015 Dec 23.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lung Neoplasms/*drug therapy
Pneumonectomy/*statistics & numerical data
Adenocarcinoma/pathology ; Adenocarcinoma of Lung ; Adult ; Aged ; Anemia/chemically induced ; Bevacizumab/administration & dosage ; Carboplatin/administration & dosage ; Fatigue/chemically induced ; Female ; Humans ; Hypertension/chemically induced ; Induction Chemotherapy ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Neutropenia/chemically induced ; Pemetrexed/administration & dosage ; Survival Rate ; Thrombocytopenia/chemically induced
Czasopismo naukowe
Tytuł :
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Autorzy :
Li N; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Ou W
Yang H
Liu QW
Zhang SL
Wang BX
Wang SY
Pokaż więcej
Źródło :
Cancer [Cancer] 2014 May 01; Vol. 120 (9), pp. 1379-86. Date of Electronic Publication: 2014 Jan 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Adenocarcinoma/*drug therapy
Adenocarcinoma/*enzymology
Antimetabolites, Antineoplastic/*therapeutic use
ErbB Receptors/*biosynthesis
Glutamates/*therapeutic use
Guanine/*analogs & derivatives
Lung Neoplasms/*drug therapy
Lung Neoplasms/*enzymology
Protein Kinase Inhibitors/*therapeutic use
Quinazolines/*therapeutic use
Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adenocarcinoma of Lung ; Adult ; Aged ; Antimetabolites, Antineoplastic/adverse effects ; ErbB Receptors/genetics ; Erlotinib Hydrochloride ; Female ; Gene Dosage ; Glutamates/adverse effects ; Guanine/adverse effects ; Guanine/therapeutic use ; Humans ; In Situ Hybridization, Fluorescence ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Pemetrexed ; Protein Kinase Inhibitors/adverse effects ; Quinazolines/adverse effects
Czasopismo naukowe
Tytuł :
The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis.
Autorzy :
Zhang SS; 1] Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China [2] Guangdong Esophageal Cancer Research Institute, Guangzhou, People's Republic of China [3] Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
Yang H
Luo KJ
Huang QY
Chen JY
Yang F
Cai XL
Xie X
Liu QW
Bella AE
Hu RG
Wen J
Hu Y
Fu JH
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2013 Nov 26; Vol. 109 (11), pp. 2894-903. Date of Electronic Publication: 2013 Nov 07.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Body Mass Index*
Adenocarcinoma/*mortality
Adenocarcinoma/*surgery
Carcinoma, Squamous Cell/*mortality
Carcinoma, Squamous Cell/*surgery
Esophageal Neoplasms/*mortality
Esophageal Neoplasms/*surgery
Postoperative Complications/*epidemiology
Adenocarcinoma/diagnosis ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/diagnosis ; China/epidemiology ; Cohort Studies ; Esophageal Neoplasms/diagnosis ; Esophageal Squamous Cell Carcinoma ; Female ; Humans ; Male ; Middle Aged ; Postoperative Complications/diagnosis ; Prognosis ; Survival Analysis
SCR Disease Name :
Adenocarcinoma Of Esophagus
Czasopismo naukowe
Tytuł :
The inhibitory effects of NKX3.1 on IGF-1R expression and its signalling pathway in human prostatic carcinoma PC3 cells.
Autorzy :
Zhang PJ; Institution of Biochemistry and Molecular Biology, Medical School of Shandong University, Jinan, China.
Hu XY
Liu CY
Chen ZB
Ni NN
Yu Y
Yang LN
Huang ZQ
Liu QW
Jiang AL
Pokaż więcej
Źródło :
Asian journal of andrology [Asian J Androl] 2012 May; Vol. 14 (3), pp. 493-8. Date of Electronic Publication: 2011 Dec 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*genetics
Gene Expression Regulation, Neoplastic/*genetics
Homeodomain Proteins/*genetics
Prostatic Neoplasms/*genetics
Receptor, IGF Type 1/*genetics
Transcription Factors/*genetics
Adenocarcinoma/drug therapy ; Adenocarcinoma/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Down-Regulation ; Gene Expression Regulation, Neoplastic/drug effects ; Homeodomain Proteins/metabolism ; Humans ; Insulin-Like Growth Factor I/pharmacology ; Male ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/metabolism ; RNA, Messenger/metabolism ; Receptor, IGF Type 1/metabolism ; Signal Transduction/drug effects ; Transcription Factors/metabolism ; Transfection
Czasopismo naukowe
Tytuł :
Emodin induces apoptosis in human prostate cancer cell LNCaP.
Autorzy :
Yu CX; Department of Biochemistry and Molecular Biology, Shandong University School of Medicine, Jinan, China.
Zhang XQ
Kang LD
Zhang PJ
Chen WW
Liu WW
Liu QW
Zhang JY
Pokaż więcej
Źródło :
Asian journal of andrology [Asian J Androl] 2008 Jul; Vol. 10 (4), pp. 625-34.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*pathology
Apoptosis/*drug effects
Emodin/*pharmacology
Prostatic Neoplasms/*pathology
Protein Kinase Inhibitors/*pharmacology
Adenocarcinoma/metabolism ; Caspase 3/metabolism ; Caspase 9/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; Humans ; Male ; Prostate-Specific Antigen/metabolism ; Prostatic Neoplasms/metabolism ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Receptors, Androgen/metabolism ; Tumor Suppressor Protein p53/metabolism ; bcl-2-Associated X Protein/metabolism
Czasopismo naukowe
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies